Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 5,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: Tobacco Dependence Treatment, Lung Cancer Screening
Interventions: External Facilitation; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
Interventions: HC-5404-FU; Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more

Conditions: Solid Tumor
Interventions: NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2; Biological
Lead sponsor: PACT Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Orange, California + 6 more

Conditions: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
Interventions: Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine, Aldesleukin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Extensive Stage Small Cell Lung Carcinoma
Interventions: Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Duarte, California • South Pasadena, California • Boston, Massachusetts

Conditions: Cancer, Cancer Cachexia, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure, Rheumatoid Arthritis
Interventions: Fish oil supplement; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Electronic health record review, Medical Device Usage and Evaluation, Physical functions assessments, Positron Emission Tomography (PET), Survey Administration; Procedure · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Lung Cancer
Interventions: Temozolomide; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Waukesha, Wisconsin

Conditions: Lung Cancer, Non-Small Cell
Interventions: pazopanib, erlotinib, pemetrexed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Aurora, Colorado • Buffalo, New York • Nashville, Tennessee

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
Interventions: Capmatinib, Trametinib; Drug
Lead sponsor: Collin Blakely; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-small Cell Lung Cancer
Interventions: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more

Conditions: Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: Docetaxel-Carboplatin; Drug
Lead sponsor: Michael Mann; Network
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Adenocarcinoma of Lung, Stage IV
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non Small Cell Lung Cancer
Interventions: Lobectomy; Procedure
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
Interventions: Berzosertib, Biopsy Specimen, Biospecimen Collection, Computed Tomography, Irinotecan Hydrochloride; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more

Conditions: Non Small Cell Lung Cancer
Interventions: Bortezomib, Carboplatin, Docetaxel; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions: RNDO-564, Pembrolizumab; Drug
Lead sponsor: Rondo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more

Conditions: NSCLC Stage IV
Interventions: Pembrolizumab, Radiation, Chemotherapy; Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Malnutrition, Weight Changes
Interventions: physiologic testing, questionnaire administration, management of therapy complications, radiation therapy; Other · Procedure · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 50 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer Screening
Interventions: Sybil Artificial Intelligence (AI) screening; Diagnostic Test
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 80 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2038
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Carcinoma, Non-small Cell Lung
Interventions: Tarceva (Erlotinib); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: bexarotene; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • Pasadena, California + 17 more

Conditions: Small Cell Lung Carcinoma
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more

Search by objective public record fields.

ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Lung Cancer Mutation Consortium Protocol

Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

Effects of Radiation Therapy on the Body in Patients With Stage III Non-Small Cell Lung Cancer

LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)